Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Amylyx Pharmaceuticals Inc. (AMLX) Insider Trading Activity
Healthcare • Biotechnology • 384 employees
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Total Value
-$75,691.19
Total Shares
37,283
Average Trade Value
-$6,307.60
Most Active Insider
Klee Justin B.
Total Activity: $242,789
Largest Single Transaction
$99,993
by Klee Justin B. on Nov 4, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Co-chief Executive Officer
|
Mar 3, 2025 | 4,595 | $14,549 | 3,196,652 (-0.1%) | Sale | |
|
Co-chief Executive Officer
|
Mar 3, 2025 | 4,595 | $14,483 | 3,196,648 (-0.1%) | Sale | |
|
Chief Legal Officer
|
Mar 3, 2025 | 1,611 | $5,022 | 133,310 (-1.2%) | Sale | |
|
Chief Legal Officer
|
Feb 24, 2025 | 4,169 | $13,145 | 134,921 (-3.1%) | Sale | |
|
Co-chief Executive Officer
|
Feb 5, 2025 | 36,310 | $57,007 | 3,201,243 (+1.1%) | Exercise/Conversion | |
|
Chief Legal Officer
|
Feb 3, 2025 | 3,678 | $12,839 | 139,090 (-2.6%) | Sale | |
|
Co-chief Executive Officer
|
Feb 3, 2025 | 11,851 | $41,108 | 3,201,247 (-0.4%) | Sale | |
|
Co-chief Executive Officer
|
Feb 3, 2025 | 11,855 | $41,104 | 3,164,933 (-0.4%) | Sale | |
|
Co-chief Executive Officer
|
Jan 6, 2025 | 7,471 | $30,202 | 3,176,788 (-0.2%) | Sale | |
|
Co-chief Executive Officer
|
Jan 6, 2025 | 7,471 | $30,232 | 3,213,098 (-0.2%) | Sale | |
|
Chief Medical Officer
|
Dec 2, 2024 | 5,421 | $30,007 | 138,380 (-3.9%) | Sale | |
|
Co-chief Executive Officer
|
Nov 4, 2024 | 63,690 | $99,993 | 3,184,259 (+2.0%) | Exercise/Conversion |